Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence

GP2 is a HER2-derived, HLA-A2+ restricted peptide. Phase I studies showed GP2 administered with GM-CSF to be safe and immunogenic. Here we report the primary analysis of a prospective, randomized, multicenter phase II adjuvant trial conducted to determine the vaccine's efficacy. The trial enrol...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittendorf, Elizabeth A., Ardavanis, Alexandros, Litton, Jennifer K., Shumway, Nathan M., Hale, Diane F., Murray, James L., Perez, Sonia A., Ponniah, Sathibalan, Baxevanis, Constantin N., Papamichail, Michael, Peoples, George E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323226/
https://www.ncbi.nlm.nih.gov/pubmed/27589688
http://dx.doi.org/10.18632/oncotarget.11751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323226/
https://www.ncbi.nlm.nih.gov/pubmed/27589688
http://dx.doi.org/10.18632/oncotarget.11751

Ejemplares similares